-
1
-
-
84874784306
-
Molecular circuits in thrombosis and inflammation
-
Esmon CT. Molecular circuits in thrombosis and inflammation. Thromb Haemost 2013;109: 416-20.
-
(2013)
Thromb Haemost
, vol.109
, pp. 416-420
-
-
Esmon, C.T.1
-
2
-
-
84855371090
-
Regulation of the inflammatory response in cardiac repair
-
Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res 2012;110:159-73.
-
(2012)
Circ Res
, vol.110
, pp. 159-173
-
-
Frangogiannis, N.G.1
-
3
-
-
0036258785
-
Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells
-
Baj-Krzyworzeka M, Majka M, Pratico D, et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 2002;30:450-9.
-
(2002)
Exp Hematol
, vol.30
, pp. 450-459
-
-
Baj-Krzyworzeka, M.1
Majka, M.2
Pratico, D.3
-
4
-
-
24744432090
-
Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure
-
Pignatelli P, De Biase L, Lenti L, et al. Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure. Blood 2005;106:1992-4.
-
(2005)
Blood
, vol.106
, pp. 1992-1994
-
-
Pignatelli, P.1
De Biase, L.2
Lenti, L.3
-
5
-
-
0034625079
-
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction
-
Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-53.
-
(2000)
Circulation
, vol.101
, pp. 2149-2153
-
-
Ridker, P.M.1
Rifai, N.2
Pfeffer, M.3
-
6
-
-
84882582318
-
Cardiovascular effects of tumour necrosis factor alpha antagonism in patients with acute myocardial infarction: A first in human study
-
Padfield GJ, Din JN, Koushiappi E, et al. Cardiovascular effects of tumour necrosis factor alpha antagonism in patients with acute myocardial infarction: a first in human study. Heart 2013;99:1330-5.
-
(2013)
Heart
, vol.99
, pp. 1330-1335
-
-
Padfield, G.J.1
Din, J.N.2
Koushiappi, E.3
-
7
-
-
0037406233
-
Meta-analysis of corticosteroid treatment in acute myocardial infarction
-
Giugliano GR, Giugliano RP, Gibson CM, et al. Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol 2003;91:1055-9.
-
(2003)
Am J Cardiol
, vol.91
, pp. 1055-1059
-
-
Giugliano, G.R.1
Giugliano, R.P.2
Gibson, C.M.3
-
8
-
-
77951665667
-
Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study)
-
Abbate A, Kontos MC, Grizzard JD, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 2010;105:1371-7 e1.
-
(2010)
Am J Cardiol
, vol.105
-
-
Abbate, A.1
Kontos, M.C.2
Grizzard, J.D.3
-
9
-
-
0041732120
-
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial
-
Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003;108:1176-83.
-
(2003)
Circulation
, vol.108
, pp. 1176-1183
-
-
Mahaffey, K.W.1
Granger, C.B.2
Nicolau, J.C.3
-
10
-
-
0042917638
-
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial
-
Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003;108:1184-90.
-
(2003)
Circulation
, vol.108
, pp. 1184-1190
-
-
Granger, C.B.1
Mahaffey, K.W.2
Weaver, W.D.3
-
11
-
-
33845981823
-
Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial
-
Armstrong PW, Granger CB, Adams PX, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007;297:43-51.
-
(2007)
JAMA
, vol.297
, pp. 43-51
-
-
Armstrong, P.W.1
Granger, C.B.2
Adams, P.X.3
-
12
-
-
22544476866
-
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: A substudy of the COMMA trial
-
Theroux P, Armstrong PW, Mahaffey KW, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 2005;26:1964-70.
-
(2005)
Eur Heart J
, vol.26
, pp. 1964-1970
-
-
Theroux, P.1
Armstrong, P.W.2
Mahaffey, K.W.3
-
13
-
-
11144355760
-
Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
-
Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602.
-
(2004)
Circulation
, vol.109
, pp. 1594-1602
-
-
Mann, D.L.1
McMurray, J.J.2
Packer, M.3
|